All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Legend Biotech, Pfizer, Roche, and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
ASH 2020| Practice-changing and breakthrough abstracts in multiple myeloma
Did you miss ASH 2020? The Multiple Myeloma Hub attended the virtual 62nd ASH Annual Meeting & Exposition, December, 5–8 2020, and has developed two resources in collaboration with our Steering Committee on the abstracts presented regarding multiple myeloma (MM) that could impact your clinical practice in the near future.
In the first downloadable resource, 'practice-changing abstracts', you will find comments from the Multiple Myeloma Hub Steering Committee members about the role of autologous stem cell transplant in the era of novel agents, and the latest updates on new combinations and therapy-sequencing strategies to achieve deeper and more durable responses.
Our second resource, 'breakthrough abstracts', covers the most exciting news about monitoring MM with less-invasive techniques and promising alternative targets to treat refractory disease. Discover underlying resistance mechanisms that could help to early identify relapse or fundament new drug combinations. Find here, the initial results obtained with novel targeted agents and the latest about BCMA-directed immunotherapies (bispecific antibodies and CAR T-cells) in clinical development.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content